Victoza is the brand name for Liraglutide. The drug we are primarily interested in is Semaglutide. Both Semaglutide and Liraglutide are GLP-1 receptor agonists.
It's worth doing your own research and consulting a doctor but the experts I've spoken to (academics and clinicians) along with the studies state that:
"GLP-1 analogues did not increase the risk for pancreatic cancer when compared to other treatments" (from a Nature Scientific Reports meta-analysis paper published in 2019) [1].
Victoza is the brand name for Liraglutide. The drug we are primarily interested in is Semaglutide. Both Semaglutide and Liraglutide are GLP-1 receptor agonists.
It's worth doing your own research and consulting a doctor but the experts I've spoken to (academics and clinicians) along with the studies state that: "GLP-1 analogues did not increase the risk for pancreatic cancer when compared to other treatments" (from a Nature Scientific Reports meta-analysis paper published in 2019) [1].
Here is the postmarket FDA safety information on Victoza if you are interested: https://www.fda.gov/drugs/postmarket-drug-safety-information...
[1] https://www.nature.com/articles/s41598-019-38956-2